A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

PHASE2CompletedINTERVENTIONAL
Enrollment

352

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Canagliflozin 100 mg

Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.

DRUG

Canagliflozin 300 mg

Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.

DRUG

Placebo

Matching placebo capsule will be taken orally, before the first meal of the day.

Trial Locations (53)

Unknown

Little Rock

Concord

La Jolla

Los Angeles

Los Gatos

Northridge

Orange

San Francisco

Temecula

Tustin

Ventura

Walnut Creek

Denver

Miami

Palm Harbor

Atlanta

Honolulu

Council Bluffs

Des Moines

Baton Rouge

Rockville

Billings

Omaha

El Paso

Las Vegas

Nashua

Billings

Smithtown

Morehead City

Columbus

Mentor

Philadelphia

Greer

Bloomington

Arlington

Austin

Dallas

El Paso

Houston

San Antonio

Schertz

Tomball

Ogden

Salt Lake City

Spokane

Milwaukee

Calgary

London

Oakville

Thornhill

Toronto

Laval

Sainte-Foy

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02139943 - A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM) | Biotech Hunter | Biotech Hunter